Cobalamin and folate binding proteins in human tumour tissue

K SHEPPARD, DA BRADBURY, JM DAVIES, DR RYRIE
From the Haematology Department, City Hospital, Nottingham NG5 1PB

SUMMARY The serum of an 84 year old man with disseminated carcinoma was found to contain extremely high concentrations of cobalamin and of a cobalamin binding protein with transcobalamin I characteristics. Tumour tissue samples obtained at necropsy contained considerably higher concentrations of cobalamin binding protein (R-binder) than normal tissues. Tumour tissues also contained increased concentrations of specific folate binding protein. In all tissues studied a close correlation existed between unsaturated cobalamin and unsaturated folate binding and between total cobalamin and total folate binding. These results suggest related mechanisms for the synthesis of cobalamin binding proteins of the R-binder class and folate binding proteins by tumour tissue.

Increased serum concentrations of cobalamin (vitamin B12) and of the cobalamin binding protein transcobalamin I, an R-binder, are found in at least 6% of patients with cancer. Hepatocellular carcinoma tissue has been found to contain 10 times as much cobalamin binding protein as normal liver tissue from the same patient, and it has therefore been suggested that tumour tissue may be the source of the high serum transcobalamin I values found in patients with cancer. Monitoring of serum cobalamin and cobalamin binding protein may be of particular clinical value in the initial assessment and subsequent monitoring of response to treatment in patients with variants of hepatocellular carcinoma associated with increased cobalamin binding protein synthesis.

In separate studies serum concentrations of specific folate binding protein have been found to be raised in some patients with cancer, and Corrocher et al. 6 reported the presence of slightly increased amounts of folate binding protein in malignant tumours from the gastrointestinal tract compared with normal mucosa.

A high serum cobalamin concentration associated with a considerably increased level of cobalamin binding was found in an 84 year old man with widely disseminated carcinoma. The subsequent availability of tumour tissue allowed a comparative study of folate binding protein and cobalamin binding protein in tumour and normal tissues from the patient.

Material and methods
Tumour tissue and adjacent normal tissue was obtained at necropsy. Histological examination of various affected organs showed involvement by anaplastic carcinoma. The site of the primary lesion could not be determined with certainty. Serum obtained before death showed that the α-fetoprotein concentration was not raised, and hepatitis B surface antigen was not detected.

SERUM STUDIES
Serum total corrinoids (cobalamin plus its analogues capable of binding to R-binder), cobalamin, folate, and red cell folate were estimated by radioisotopic assay. Unsaturated cobalamin binding was determined by the coated charcoal technique of Lau et al. using 57Co cyanocobalamin of specific activity 6·7–11·1 MBq/μg (Amersham International plc). The labelled transcobalamin were separated into three components (transcobalamin I, II, and III) by chromatography on DE23 cellulose. Unsaturated folate binding was determined with 125I folate (Becton Dickinson UK Ltd) using extended incubation with coated charcoal to ensure specificity for folate binding protein.

TISSUE STUDIES
Tumour and histologically normal tissue samples were stored without fixation at −30°C before study. Roughly 20 mg portions of each tissue were thawed and homogenised in 5 ml of distilled water. The sus-
Cobalamin and folate binding proteins in human tumour tissue

Table 1 Results of serum assays

<table>
<thead>
<tr>
<th>Serum value</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ng/l)</td>
<td></td>
</tr>
<tr>
<td>Total corrinoids</td>
<td>32 500</td>
</tr>
<tr>
<td>Cobalamin</td>
<td>25 000</td>
</tr>
<tr>
<td>Unsaturated cobalamin binding</td>
<td>26 100</td>
</tr>
<tr>
<td>Transcobalamin I</td>
<td>22 500</td>
</tr>
<tr>
<td>Transcobalamin II</td>
<td>490</td>
</tr>
<tr>
<td>Transcobalamin III</td>
<td>3110</td>
</tr>
<tr>
<td>Unsaturated folate binding</td>
<td>70</td>
</tr>
</tbody>
</table>

Transcobalamin values are expressed in terms of unsaturated cobalamin binding capacity.

Pensions were centrifuged at 2500 g for 20 min and the supernatants passed through 0.8 μm pore size cellulose acetate membrane filters. The total protein concentration of each solution was determined using a sensitive microtechnique.10

Total corrinoids, folate, unsaturated cobalamin binding, and unsaturated folate binding were determined on appropriate dilutions of the tissue extracts, as described for serum. Total folate binding was estimated after removal of endogenous folate by acid exposure and dextran coated charcoal separation.9 The labelled cobalamin binding proteins were chromatographed on Sephadex G-200 using 40 mmol/l phosphate buffer, pH 7.4, containing 0.5 mol/l sodium chloride, to enable the type of binding protein present to be established.11

Results

The serum showed a considerably increased unsaturated cobalamin binding capacity with high corrinoid and cobalamin concentrations (Table 1). DE23 chromatography confirmed that the major increase in cobalamin binding was due to an increase in transcobalamin I. Serum and red cell folate and serum folate binding protein values were within normal limits.

Tissue studies showed that, with the exception of normal liver corrinoids, tumour tissue contained higher concentrations of corrinoids and folate than normal tissue. Tumour unsaturated cobalamin and folate binding was significantly greater than that of normal tissue (Table 2). Sephadex G-200 chromatography of tissue cobalamin binders showed a single peak in the characteristic position of R-binder in all cases except normal lung tissue, which showed R-binder plus a small transcobalamin II fraction amounting to about 5% of the binding activity present. This may have been derived from alveolar macrophages, which are capable of transcobalamin II synthesis.12 A strong correlation was found between unsaturated cobalamin binding and unsaturated folate binding protein in all the tissues studied (r = 0.89, p < 0.001 by paired t test). When total cobalamin binding, obtained by addition of unsaturated cobalamin binding to the tissue corrinoid concentration, was compared with total folate binding protein, determined using acid dissociation of endogenous folate from folate binding protein, the correlation was still apparent, though to a less significant degree (r = 0.71, p < 0.05). The manipulations entailed in determining the total binding capacities would, however, be subject to considerably greater error than determination of unsaturated binding alone.

Discussion

The high concentrations of cobalamin binding protein in the tumour tissues studied suggest that these tissues were the source of the increased binding protein in the serum, although definitive studies of protein synthesis were not undertaken in this case. The strong correlation between cobalamin binding and folate binding protein suggests that the mechanism of production within the tissues was closely related. The possibility of a relation in the synthesis of these proteins is not unexpected. Both cobalamin binding proteins of the R-binder class and folate binding protein have been reported to be present in breast milk,13 14 plasma,13 15 and in the secondary granules

Table 2 Cobalamin and folate binding values obtained using aqueous tissue extracts

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Cobalamin binding (ng/g)</th>
<th>Folate binding (ng/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unsaturated</td>
<td>Total</td>
</tr>
<tr>
<td>Normal brain</td>
<td>&lt;10</td>
<td>770</td>
</tr>
<tr>
<td>Brain tumour</td>
<td>2136</td>
<td>2827</td>
</tr>
<tr>
<td>Normal liver</td>
<td>&lt;10</td>
<td>5440</td>
</tr>
<tr>
<td>Liver tumour</td>
<td>2120</td>
<td>2542</td>
</tr>
<tr>
<td>Normal heart</td>
<td>&lt;10</td>
<td>407</td>
</tr>
<tr>
<td>Heart tumour</td>
<td>725</td>
<td>1146</td>
</tr>
<tr>
<td>Normal lung</td>
<td>403</td>
<td>1257</td>
</tr>
<tr>
<td>Lung tumour</td>
<td>3045</td>
<td>3296</td>
</tr>
<tr>
<td>Duodenal tumour</td>
<td>188</td>
<td>549</td>
</tr>
<tr>
<td>Thyroid tumour</td>
<td>52</td>
<td>480</td>
</tr>
</tbody>
</table>

Values are expressed as nanogram of binding per gram of soluble protein.
of neutrophils. We have also found folate binding protein in saliva and semen (unpublished observations), both of which contain R-binder. R-binders and folate binding protein are similar in that both are glycoproteins showing heterogeneity on isoelectric focusing and appear to have similar roles in the plasma in that cobalamin or folate carried on these proteins is apparently available only to binding sites in the liver.

Although concentrations of both folate and cobalamin binding proteins were clearly increased in the tumour tissues examined, there were no detectable abnormalities of serum folate binding protein values. This discrepancy may relate to differences in effectiveness in plasma clearance of tumour derived cobalamin and folate binding proteins in this patient. It has been suggested that tumour derived transcobalamin I may have a slow clearance rate owing to increased sialation of the protein. The effect of sialation on the clearance of folate binding protein has not been described.

This study demonstrates that abnormalities of folate and cobalamin binding proteins may be detectable in both the serum and tumour tissue of some patients with malignant disease. Furthermore, other studies have shown that such abnormalities may not be uncommon. The application of cobalamin and folate binding capacity assays to patients with suspected or proved malignancy may be of value in both diagnosis and monitoring of subsequent treatment in those patients with increased serum concentrations of these proteins.

References

Cobalamin and folate binding proteins in human tumour tissue.

K Sheppard, D A Bradbury, J M Davies and D R Ryrie

*J Clin Pathol* 1984 37: 1336-1338
doi: 10.1136/jcp.37.12.1336

Updated information and services can be found at:
[http://jcp.bmj.com/content/37/12/1336](http://jcp.bmj.com/content/37/12/1336)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)